INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

Lexeo Therapeutics, Inc.

LXEOCIK 0001907108

EDGAR filingsOpen in network
Price$2.90
1 year-65.2%
Disclosed transactions42
Buys / sells0 / 17
Max Insider Score47
Connections with evidence13

LXEO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A$6,097
2,306 sh
Sep 14, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Tanguler TolgaDirector · Jun 29, 2026
  • ← Insider ofevidence
    Cooperstone BrendaDirector · Jun 29, 2026
  • ← Insider ofevidence
    Van Hauwermeiren TimothyDirector · Jun 29, 2026
  • ← Insider ofevidence
Sep 28, 2026
traded Sep 14, 2026
+14d
SEC FORM 4

Evidence

2
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
145.5K sh
Sep 24, 2026Sep 28, 2026
traded Sep 24, 2026
+4dSEC FORM 4

Evidence

15
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A$5,579
2,110 sh
Sep 14, 2026Sep 28, 2026
traded Sep 14, 2026
+14dSEC FORM 4

Evidence

5
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
54.8K sh
Sep 24, 2026Sep 28, 2026
traded Sep 24, 2026
+4dSEC FORM 4

Evidence

15
BP
Bhalla Narinder PalChief Medical Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A$9,713
2,714 sh
Sep 14, 2026Sep 28, 2026
traded Sep 14, 2026
+14dSEC FORM 4

Evidence

5
BP
Bhalla Narinder PalChief Medical Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
54.8K sh
Sep 24, 2026Sep 28, 2026
traded Sep 24, 2026
+4dSEC FORM 4

Evidence

5
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
54.8K sh
Sep 24, 2026Sep 28, 2026
traded Sep 24, 2026
+4dSEC FORM 4

Evidence

27
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$17K
3,345 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

27
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$6,464
1,304 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

27
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$20K
4,117 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

21
BP
Bhalla Narinder PalChief Medical Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
55.0K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

47
BP
Bhalla Narinder PalChief Medical Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$99K
22.3K sh
Jul 1, 2026Jul 1, 2026
traded Jul 1, 2026
+0dSEC FORM 4

Evidence

13
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
12.0K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

9
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
67.0K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

36
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$21K
4,641 sh
Jul 1, 2026Jul 1, 2026
traded Jul 1, 2026
+0dSEC FORM 4

Evidence

39
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$116K
25.9K sh
Jul 1, 2026Jul 1, 2026
traded Jul 1, 2026
+0dSEC FORM 4

Evidence

9
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
12.1K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

32
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$21K
4,666 sh
Jul 1, 2026Jul 1, 2026
traded Jul 1, 2026
+0dSEC FORM 4

Evidence

9
VT
Van Hauwermeiren TimothyDirector
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
35.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
CB
Cooperstone BrendaDirector
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
35.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
TT
Tanguler TolgaDirector
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
35.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
AK
Agger Mette KirstineDirector
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
35.0K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

22
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$17K
3,342 sh
May 18, 2026May 20, 2026
traded May 18, 2026
+2dSEC FORM 4

Evidence

22
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$6,606
1,302 sh
May 18, 2026May 20, 2026
traded May 18, 2026
+2dSEC FORM 4

Evidence

9
SL
Sepp-Lorenzino LauraDirector
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
50.0K sh
Apr 28, 2026Apr 30, 2026
traded Apr 28, 2026
+2dSEC FORM 4

Evidence

11
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$313K
55.0K sh
Apr 6, 2026Apr 7, 2026
traded Apr 6, 2026
+1dSEC FORM 4

Evidence

5
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A$16K
5,930 sh
Mar 13, 2026Mar 17, 2026
traded Mar 13, 2026
+4dSEC FORM 4

Evidence

22
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$19K
3,016 sh
Feb 18, 2026Feb 20, 2026
traded Feb 18, 2026
+2dSEC FORM 4

Evidence

25
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$65K
10.2K sh
Feb 18, 2026Feb 20, 2026
traded Feb 18, 2026
+2dSEC FORM 4

Evidence

9
BP
Bhalla Narinder PalChief Medical Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
297.0K sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

9
BP
Bhalla Narinder PalChief Medical Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
49.5K sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

17
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
65.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
161.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

21
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
44.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

5
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
646.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

5
OM
Otero Jose ManuelChief Operating Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
260.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
226.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

36
AE
Adler EricChief Medical Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$5,701
615 sh
Nov 18, 2025Nov 20, 2025
traded Nov 18, 2025
+2dSEC FORM 4

Evidence

36
RJ
Robertson JennyChief Legal Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$5,089
549 sh
Nov 18, 2025Nov 20, 2025
traded Nov 18, 2025
+2dSEC FORM 4

Evidence

36
SS
See Tai SandiChief Development Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$3,578
386 sh
Nov 18, 2025Nov 20, 2025
traded Nov 18, 2025
+2dSEC FORM 4

Evidence

36
TN
Townsend Richard NolanDirector, Chief Executive Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$10K
1,127 sh
Nov 18, 2025Nov 20, 2025
traded Nov 18, 2025
+2dSEC FORM 4

Evidence

36
OM
Otero Jose ManuelChief Technical Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$6,684
721 sh
Aug 18, 2025Nov 20, 2025
traded Aug 18, 2025
+94dSEC FORM 4

Evidence

Agger Mette Kirstine
Director · Jun 29, 2026
  • ← Insider ofevidence
    Sepp-Lorenzino LauraDirector · Apr 30, 2026
  • ← Insider ofevidence
    Bhalla Narinder PalChief Medical Officer · Feb 17, 2026
  • ← Insider ofevidence
    Tamayo Louis EdwardChief Financial Officer · Feb 6, 2026
  • ← Insider ofevidence
    See Tai SandiChief Development Officer · Nov 20, 2025
  • ← Insider ofevidence
    Robertson JennyChief Legal Officer · Nov 20, 2025
  • ← Insider ofevidence
    Otero Jose ManuelChief Technical Officer · Nov 20, 2025
  • ← Insider ofevidence
    Townsend Richard NolanDirector, Chief Executive Officer · Nov 20, 2025
  • ← Insider ofevidence
    Adler EricChief Medical Officer · Nov 20, 2025